|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Alcon Research |
| Information provided by: | Alcon Research |
| ClinicalTrials.gov Identifier: | NCT00041483 |
Purpose
The purpose of this study is to demonstrate that Anecortave Acetate is as effective after twelve months of treatment as photodynamic therapy (PDT) with Visudyne in patients eligible for initial PDT treatment for wet age-related macular degeneration.
| Condition | Intervention | Phase |
|
Macular Degeneration |
Drug: Anecortave Acetate |
Phase III |
| Genetics Home Reference related topics: | X-linked juvenile retinoschisis |
| MedlinePlus related topics: | Macular Degeneration |
| ChemIDplus related topics: | Verteporfin Anecortave acetate |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Active Control, Single Group Assignment, Safety/Efficacy Study |
| Official Title: | Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD. |
Eligibility
| Ages Eligible for Study: | 50 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Patients of any race, either gender, aged 50 years and above, diagnosed with subfoveal CNV due to AMD with best corrected logMAR visual acuity of 20/40 (snellen equivalent) to 20/400 (Snellen equivalent) in the study eye. Clinically relevant concomitant diseases will be excluded.
Contacts and Locations
More Information
Click here for more information about this study: A Phase III Clinical Trial for AMD: Information for Potential Participants 
  |
| Study ID Numbers: | C-01-99 |
| First Received: | July 9, 2002 |
| Last Updated: | July 21, 2008 |
| ClinicalTrials.gov Identifier: | NCT00041483 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|